Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite
- 8 October 2008
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 85 (1), 78-85
- https://doi.org/10.1038/clpt.2008.186
Abstract
The effects of single doses of intravenous (IV) ciprofloxacin and rifampin and of multiple doses of rifampin on glyburide exposure and blood glucose levels were investigated in nine healthy volunteers. A single IV dose of rifampin significantly increased the area under the concentration–time curve (AUC) of glyburide and its metabolite. Blood glucose levels were significantly lower than those observed after dosing with glyburide alone. Multiple doses of rifampin induced an increase in liver enzyme levels, leading to a marked decrease in glyburide exposure and blood glucose levels. When IV rifampin was administered after multiple doses of rifampin, the inhibition of hepatic uptake transporters masked the induction effect; however, the relative changes in AUC for glyburide and its hydroxyl metabolite were similar to those seen under noninduced conditions. The studies reported here demonstrate how measurements of the levels of both the parent drug and its primary metabolite are useful in unmasking simultaneous drug–drug induction and inhibition effects and in characterizing enzymatic vs. transporter mechanisms. Clinical Pharmacology & Therapeutics (2008); 85 , 1, 78–85 doi:10.1038/clpt.2008.186Keywords
This publication has 34 references indexed in Scilit:
- Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and MetabolismThe Journal of pharmacology and experimental therapeutics, 2006
- PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISMDrug Metabolism and Disposition, 2006
- Development of a fluorescence-based assay for screening of modulators of human Organic Anion Transporter 1B3 (OATP1B3)European Journal of Pharmaceutics and Biopharmaceutics, 2006
- CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-BPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2005
- HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATIONDrug Metabolism and Disposition, 2004
- Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter InterplayThe Journal of pharmacology and experimental therapeutics, 2003
- DISPOSITION OF TACROLIMUS IN ISOLATED PERFUSED RAT LIVER: INFLUENCE OF TROLEANDOMYCIN, CYCLOSPORINE, AND GG918Drug Metabolism and Disposition, 2003
- Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin AJournal of Pharmacology and Experimental Therapeutics, 2003
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting PolypeptidePublished by Elsevier BV ,2000